Biotech Values

[DewDiligence]

JAGX IPOs 3.29M* shares @$7.00, raising ~$21.6M*:

http://finance.yahoo.com/news/jaguar-animal-health-inc-announces-134800787.html

Jaguar Animal Health, Inc. is an animal health company [that much I could have guessed, LOL] focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals.

Canalevia is Jaguar’s lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Neonorm Calf is the company’s lead non-prescription product. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm is a standardized botanical extract derived from the Croton lechleri tree. Canalevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has filed nine Investigational New Animal Drug applications, or INADs, with the FDA and intends to develop species-specific formulations of Neonorm in six additional target species, and formulations of Canalevia for cats, horses and dogs.

The stock is down 3% on its first day of trading.